Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study.
Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study.
复制标题
DOI：
10.1136/bmj-2021-068848
复制
发表时间：
2021-12-15
期刊：
影响因子：
--
通讯作者：
Tseng HF
中科院分区：
文献类型：
--
作者：
Bruxvoort KJ;Sy LS;Qian L;Ackerson BK;Luo Y;Lee GS;Tian Y;Florea A;Aragones M;Tubert JE;Takhar HS;Ku JH;Paila YD;Talarico CA;Tseng HF
评估mRNA-1273疫苗对SARS-CoV-2变异株的有效性，并评估其对自接种以来的时间的δ变异株的有效性。试验阴性病例对照研究。Kaiser Permanente Southern加州（KPSC）是一个综合医疗保健系统。2021年3月1日至2021年7月27日期间，SARS-CoV-2检测呈阳性的成年KPSC成员被送去进行全基因组测序或检测呈阴性。样本采集前≥14天接种两剂或一剂mRNA-1273（Moderna covid-19疫苗）与未接种covid-19疫苗相比。结果包括感染SARS-CoV-2和因covid-19住院。在每种变体类型的预先规定的分析中，在年龄、性别、人种/种族和标本采集日期方面，将检测阳性病例与检测阴性对照按1：5匹配。采用条件Logistic回归分析比较病例组与对照组的疫苗接种几率，并对混杂因素进行调整。疫苗有效性计算为（1-比值比）× 100%。该研究包括8153例病例及其配对对照。两剂疫苗有效率为86.7%（95%置信区间为84.3%至88.7%），针对δ变异体感染，98.4%（96.9%至99.1%）相对于α，90.4%（73.9%-96.5%），其他已鉴定变体为96-98%，未鉴定变体（即测序失败的标本）为79.9%（76.9%-82.5%）。δ变体的住院疫苗有效性为97.5%（92.7%至99.2%）。针对delta变体感染的疫苗有效性从接种后14-60天的94.1%（90.5%至96.3%）下降至接种后151-180天的80.0%（70.2%至86.6%）。非δ变异体的衰退不太明显。年龄≥65岁人群（75.2%，59.6%至84.8%）的三角洲感染疫苗有效性低于18-64岁人群（87.9%，85.5%至89.9%）。单剂疫苗对Delta感染的有效率为77.0%（60.7%至86.5%）。两种剂量的mRNA-1273对所有SARS-CoV-2变体都非常有效，特别是对因covid-19住院的患者。然而，随着接种后时间的延长，疫苗对delta变异体感染的有效性适度下降。
To evaluate the effectiveness of the mRNA-1273 vaccine against SARS-CoV-2 variants and assess its effectiveness against the delta variant by time since vaccination. Test negative case-control study. Kaiser Permanente Southern California (KPSC), an integrated healthcare system. Adult KPSC members with a SARS-CoV-2 positive test sent for whole genome sequencing or a negative test from 1 March 2021 to 27 July 2021. Two dose or one dose vaccination with mRNA-1273 (Moderna covid-19 vaccine) ≥14 days before specimen collection versus no covid-19 vaccination. Outcomes included infection with SARS-CoV-2 and hospital admission with covid-19. In pre-specified analyses for each variant type, test positive cases were matched 1:5 to test negative controls on age, sex, race/ethnicity, and specimen collection date. Conditional logistic regression was used to compare odds of vaccination among cases versus controls, with adjustment for confounders. Vaccine effectiveness was calculated as (1–odds ratio)×100%. The study included 8153 cases and their matched controls. Two dose vaccine effectiveness was 86.7% (95% confidence interval 84.3% to 88.7%) against infection with the delta variant, 98.4% (96.9% to 99.1%) against alpha, 90.4% (73.9% to 96.5%) against mu, 96-98% against other identified variants, and 79.9% (76.9% to 82.5%) against unidentified variants (that is, specimens that failed sequencing). Vaccine effectiveness against hospital admission with the delta variant was 97.5% (92.7% to 99.2%). Vaccine effectiveness against infection with the delta variant declined from 94.1% (90.5% to 96.3%) 14-60 days after vaccination to 80.0% (70.2% to 86.6%) 151-180 days after vaccination. Waning was less pronounced for non-delta variants. Vaccine effectiveness against delta infection was lower among people aged ≥65 years (75.2%, 59.6% to 84.8%) than those aged 18-64 years (87.9%, 85.5% to 89.9%). One dose vaccine effectiveness was 77.0% (60.7% to 86.5%) against infection with delta. Two doses of mRNA-1273 were highly effective against all SARS-CoV-2 variants, especially against hospital admission with covid-19. However, vaccine effectiveness against infection with the delta variant moderately declined with increasing time since vaccination.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.15585/mmwr.mm7037e3
发表时间：
2021-09-17
期刊：
MMWR. Morbidity and mortality weekly report
影响因子：
--
作者：
Bajema KL;Dahl RM;Prill MM;Meites E;Rodriguez-Barradas MC;Marconi VC;Beenhouwer DO;Brown ST;Holodniy M;Lucero-Obusan C;Rivera-Dominguez G;Morones RG;Whitmire A;Goldin EB;Evener SL;Tremarelli M;Tong S;Hall AJ;Schrag SJ;McMorrow M;Kobayashi M;Verani JR;Surie D;SUPERNOVA COVID-19;Surveillance Group;Surveillance Platform for Enteric and Respiratory Infectious Organisms at the VA (SUPERNOVA) COVID-19 Surveillance Group
通讯作者：
Surveillance Platform for Enteric and Respiratory Infectious Organisms at the VA (SUPERNOVA) COVID-19 Surveillance Group
影响因子：
82.9
作者：
Chemaitelly, Hiam;Yassine, Hadi M.;Abu-Raddad, Laith J.
通讯作者：
Abu-Raddad, Laith J.
DOI：
10.1136/bmj.n1943
发表时间：
2021-08-20
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Chung H;He S;Nasreen S;Sundaram ME;Buchan SA;Wilson SE;Chen B;Calzavara A;Fell DB;Austin PC;Wilson K;Schwartz KL;Brown KA;Gubbay JB;Basta NE;Mahmud SM;Righolt CH;Svenson LW;MacDonald SE;Janjua NZ;Tadrous M;Kwong JC;Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators
通讯作者：
Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators
DOI：
10.15585/mmwr.mm7032e3
发表时间：
2021-08-13
期刊：
MMWR. Morbidity and mortality weekly report
影响因子：
--
作者：
Moline HL;Whitaker M;Deng L;Rhodes JC;Milucky J;Pham H;Patel K;Anglin O;Reingold A;Chai SJ;Alden NB;Kawasaki B;Meek J;Yousey-Hindes K;Anderson EJ;Farley MM;Ryan PA;Kim S;Nunez VT;Como-Sabetti K;Lynfield R;Sosin DM;McMullen C;Muse A;Barney G;Bennett NM;Bushey S;Shiltz J;Sutton M;Abdullah N;Talbot HK;Schaffner W;Chatelain R;Ortega J;Murthy BP;Zell E;Schrag SJ;Taylor C;Shang N;Verani JR;Havers FP
通讯作者：
Havers FP